Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Felbinac→

Felbinac Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
5728-52-9
Molecular formula
C14H12O2
Molecular weight
212.24 g/mol
Drug class
Topical non-steroidal anti-inflammatory drug (NSAID)biphenylacetic acid derivative
Mechanism of action
Inhibits cyclo-oxygenase-mediated prostaglandin synthesis in treated tissues, reducing local inflammatory pain and swelling.
Indications / reported uses
  • Topical symptomatic treatment of musculoskeletal pain and inflammation, including sprains, strains, bruises and localised osteoarthritis, using authorised gel or patch formulations

Sources: NLM MeSH — Felbinac · PubMed — Felbinac topical NSAID · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Felbinac Environmental Risk Assessment (ERA) (the Felbinac ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.